Acadia falls as rare disease therapy fails late-stage trial

Acadia Pharmaceuticals

24/09/2025 14:56

Updates

** Shares of drugmaker Acadia Pharmaceuticals ACAD.O fall 14.8% to $20.1

** Co says its experimental therapy to treat a rare metabolic condition failed to meet main goal in late-stage study

** ACAD was testing treatment ACP-101 to treat hyperphagia, or feelings of intense and persistent hunger, in patients with genetic disorder called Prader-Willi syndrome

** Says co does not plan to investigate therapy any further

** Shares of rival drugmaker Soleno Therapeutics SLNO.O rose 12.2%

** Including session's move, ACAD up 12.8% and SLNO up 44.6% YTD

 (Reporting by Christy Santhosh and Padmanabhan Ananthan)

 ((Christy.Santhosh@thomsonreuters.com))